Is trazodone appropriate for treating insomnia?

Trazodone Should NOT Be Used as First-Line Treatment for Insomnia

The American Academy of Sleep Medicine explicitly recommends AGAINST using trazodone for treating either sleep onset or sleep maintenance insomnia in adults 1. This is the most authoritative and recent guideline-level evidence available, and it should guide clinical practice.

Why Trazodone Is Not Recommended

Guideline-Based Reasoning

The 2017 AASM clinical practice guideline conducted a systematic GRADE assessment and concluded that clinicians should not use trazodone (50 mg doses studied) as treatment for insomnia versus no treatment 1. This recommendation was based on:

• Very low quality of evidence for benefits
• Insufficient data demonstrating that benefits outweigh harms
• Recognition that many patients would not choose this treatment if properly informed

The 2016 American College of Physicians evidence report similarly found insufficient or low-strength evidence for antidepressants (including trazodone) in treating insomnia disorder 2.

FDA-Approved Indication

Trazodone is FDA-approved only for major depressive disorder, NOT for insomnia 3. Its use for insomnia represents off-label prescribing without the regulatory scrutiny applied to approved hypnotics.

What the Evidence Actually Shows

Limited Efficacy Data

Recent meta-analyses reveal trazodone's modest and inconsistent effects:

• No significant improvement in total sleep time (subjective): 0.73 minutes, essentially zero benefit 4
• Improved sleep quality (subjective perception): SMD = -0.58, but this is a soft endpoint 4
• Objective total sleep time increased by only 28 minutes on polysomnography 4
• No effect on sleep latency (falling asleep) in most analyses 5

The drug shows some benefit for sleep maintenance (reducing awakenings and wake after sleep onset) 4, 6, 5, but this does not justify first-line use given safety concerns.

Significant Safety Concerns

The FDA label highlights multiple serious risks 3:

• Orthostatic hypotension and syncope - particularly dangerous in elderly patients
• Priapism - can cause permanent erectile dysfunction if not treated emergently (>4 hours requires immediate medical attention)
• Increased bleeding risk - especially with concurrent antiplatelet agents or anticoagulants
• Cognitive and motor impairment - affects driving and hazardous activities
• Hyponatremia - particularly in elderly, those on diuretics, or volume-depleted patients
• Serotonin syndrome - when combined with other serotonergic agents

Meta-analytic data confirms higher adverse event rates 4:

• 2.3 times more dropouts due to adverse effects (RR = 2.30)
• 3.7 times more sleep-related adverse effects (RR = 3.67)
• 4.3 times more overall sleep-related adverse effects (RR = 4.31)
• Specific issues: daytime drowsiness (OR = 2.53), decreased appetite (OR = 2.81) 6

Recommended First-Line Alternatives

The AASM guideline suggests using the following agents with stronger evidence 1:

For Sleep Onset Insomnia:

• Zolpidem (10 mg)
• Zaleplon (10 mg)
• Triazolam (0.25 mg)
• Ramelteon (8 mg)

For Sleep Maintenance Insomnia:

• Suvorexant (orexin receptor antagonist)
• Eszopiclone (2-3 mg)
• Doxepin (3-6 mg) - low-dose formulation specifically for insomnia
• Temazepam (15 mg)

For Both Sleep Onset and Maintenance:

• Eszopiclone
• Zolpidem
• Temazepam

These agents have low to moderate strength evidence demonstrating benefits that outweigh harms, unlike trazodone's very low quality evidence 1.

Clinical Caveats and Exceptions

When Trazodone Might Be Considered (NOT First-Line)

Trazodone may have a role as a second-line or adjunctive agent in specific scenarios:

1. Comorbid depression requiring antidepressant treatment - where insomnia is secondary to depression 7
2. Patients already on activating antidepressants (SSRIs/SNRIs) who develop insomnia 8
3. After failure of approved hypnotics or when contraindications exist to first-line agents
4. Patients with substance use history where controlled substances are contraindicated

Timing Considerations

If trazodone is used, it must be administered at least 1 hour before bedtime (not at bedtime like hypnotics) due to its pharmacokinetic profile 8. This is a common prescribing error.

Populations Requiring Extra Caution

• Elderly patients: Higher risk of falls, orthostatic hypotension, hyponatremia, and cognitive impairment 3
• Men with risk factors for priapism: Sickle cell disease, multiple myeloma, leukemia, penile anatomical abnormalities 3
• Patients on anticoagulants: Increased bleeding risk requires careful monitoring 3
• Those with cardiac conditions: QT prolongation concerns 3

Bottom Line Algorithm

For primary insomnia in adults:

1. First-line: Choose from AASM-recommended agents based on insomnia type (onset vs. maintenance) 1

2. Consider non-pharmacologic approaches: Cognitive behavioral therapy for insomnia (CBT-I) should be discussed

3. Reserve trazodone for patients with:

   • Comorbid depression requiring antidepressant treatment
   • Failed trials of approved hypnotics
   • Contraindications to first-line agents
   • Substance use history precluding controlled substances

4. Never use trazodone as initial empiric therapy for uncomplicated insomnia

The evidence is clear: trazodone lacks the quality of evidence, regulatory approval, and safety profile to justify first-line use for insomnia 1. Despite its widespread off-label use, this practice is not supported by current clinical guidelines.